↓ Skip to main content

Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, May 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

patent
6 patents
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
35 Dimensions

Readers on

mendeley
15 Mendeley
Title
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
Published in
Cancer Chemotherapy and Pharmacology, May 2010
DOI 10.1007/s00280-010-1344-7
Pubmed ID
Authors

Cao Yang, Edwin Choy, Francis J. Hornicek, Kirkham B. Wood, Joseph H. Schwab, Xianzhe Liu, Henry Mankin, Zhenfeng Duan

Abstract

To better understand the mechanisms of cytotoxicity and cell death induced by HDACI PCI-24781 in bone sarcoma cells.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 7%
United States 1 7%
Unknown 13 87%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 33%
Student > Ph. D. Student 4 27%
Student > Bachelor 1 7%
Professor > Associate Professor 1 7%
Student > Postgraduate 1 7%
Other 0 0%
Unknown 3 20%
Readers by discipline Count As %
Agricultural and Biological Sciences 5 33%
Biochemistry, Genetics and Molecular Biology 2 13%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Social Sciences 1 7%
Medicine and Dentistry 1 7%
Other 1 7%
Unknown 4 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 February 2023.
All research outputs
#4,972,158
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#244
of 2,501 outputs
Outputs of similar age
#20,793
of 97,255 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 22 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 97,255 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.